Pulse Biosciences shares surge 29.58% intraday after presenting nPulse catheter data at AF Symposium showing 65-minute procedures and high success rates.

Pulse Biosciences surged 29.58% intraday, with the company presenting nPulse catheter feasibility study data at the 31st annual AF Symposium, showing a 65-minute average procedure time and 1.3% adverse event rate, along with 100% 6-month and 96% 12-month success rates in atrial fibrillation treatment." The nPulse catheter system, designed for AF treatment, demonstrated 100% efficacy in 75 patients at 6 months and 96% efficacy in 47 patients at 12 months, according to the company.